Hemolytic anemia

References

Key articles

Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017 Jun 1;129(22):2971-9 Abstract

Hill QA, Stamps R, Massey E, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017 Feb;176(3):395-411.Full text  Abstract

Hill QA, Stamps R, Massey E, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017 Apr;177(2):208-20.Full text  Abstract

Reference articles

1. Kim Y, Park J, Kim M. Diagnostic approaches for inherited hemolytic anemia in the genetic era. Blood Res. 2017 Jun;52(2):84-94.Full text  Abstract

2. Jung HL. A new paradigm in the diagnosis of hereditary hemolytic anemia. Blood Res. 2013 Dec;48(4):237-9.Full text  Abstract

3. Nkhoma ET, Poole C, Vannappagari V, et al. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009 May-Jun;42(3):267-78.Full text  Abstract

4. Lippi G, Mattiuzzi C. Updated worldwide epidemiology of inherited erythrocyte disorders. Acta Haematol. 2020;143(3):196-203. Abstract

5. Beutler E. Red cell enzyme defects. Hematol Pathol. 1990;4(3):103-14. Abstract

6. Heller P, Best WR, Nelson RB, et al. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med. 1979 May 3;300(18):1001-5. Abstract

7. Prchal JT, Gregg XT. Red cell enzymes. Hematology Am Soc Hematol Educ Program. 2005 Jan 1;1:19-23.Full text  Abstract

8. Barcellini W, Fattizzo B. How I treat warm autoimmune hemolytic anemia. Blood. 2021 Mar 11;137(10):1283-94.Full text  Abstract

9. Tranekær S, Hansen DL, Frederiksen H. Epidemiology of secondary warm autoimmune haemolytic anaemia: a systematic review and meta-analysis. J Clin Med. 2021 Mar 17;10(6):1244.Full text  Abstract

10. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017 Jun 1;129(22):2971-9 Abstract

11. Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):690-7.Full text  Abstract

12. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009 Jan 1;1:73-9.Full text  Abstract

13. Durán S, Apte M, Alarcón GS, et al. Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort. Arthritis Rheum. 2008 Sep 15;59(9):1332-40.Full text  Abstract

14. Giannini S, Martes C. Anemia in inflammatory bowel disease. Minerva Gastroenterol Dietol. 2006 Sep;52(3):275-91. Abstract

15. Sallah S, Sigounas G, Vos P, et al. Autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma: characteristics and significance. Ann Oncol. 2000 Dec;11(12):1571-7.Full text  Abstract

16. Autore F, Pasquale R, Innocenti I, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: a comprehensive review. Cancers (Basel). 2021 Nov 19;13(22):5804.Full text  Abstract

17. Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011 May;96(5):752-61.Full text  Abstract

18. Zhou JC, Wu MQ, Peng ZM, et al. Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: a retrospective study. Medicine (Baltimore). 2020 Feb;99(7):e19015.Full text  Abstract

19. Ravindran A, Sankaran J, Jacob EK, et al. High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. Am J Hematol. 2017 Aug;92(8):E164-6.Full text  Abstract

20. Palatianos GM, Laczkovics AM, Simon P, et al. Multicentered European study on safety and effectiveness of the On-X prosthetic heart valve: intermediate follow-up. Ann Thorac Surg. 2007 Jan;83(1):40-6.Full text  Abstract

21. Bavaria JE, Desai ND, Cheung A, et al. The St Jude Medical Trifecta aortic pericardial valve: results from a global, multicenter, prospective clinical study. J Thorac Cardiovasc Surg. 2014 Feb;147(2):590-7.Full text  Abstract

22. Alkhouli M, Farooq A, Go RS, et al. Cardiac prostheses-related hemolytic anemia. Clin Cardiol. 2019 Jul;42(7):692-700.Full text  Abstract

23. Steensma DP, Hoyer JD, Fairbanks VF. Hereditary red blood cell disorders in middle eastern patients. Mayo Clin Proc. 2001 Mar;76(3):285-93. Abstract

24. Ryan K, Bain BJ, Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol. 2010 Apr;149(1):35-49.Full text  Abstract

25. Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):208-16.Full text  Abstract

26. Berentsen S, Barcellini W. Autoimmune hemolytic anemias. N Engl J Med. 2021 Oct 7;385(15):1407-19. Abstract

27. Boilève A, Gavaud A, Grignano E, et al. Acute and fatal cephalosporin-induced autoimmune haemolytic anaemia. Br J Clin Pharmacol. 2021 Apr;87(4):2152-6.Full text  Abstract

28. Lee SW, Chaiyakunapruk N, Lai NM. What G6PD-deficient individuals should really avoid. Br J Clin Pharmacol. 2017 Jan;83(1):211-2.Full text  Abstract

29. Telford RD, Sly GJ, Hahn AG, et al. Footstrike is the major cause of hemolysis during running. J Appl Physiol (1985). 2003 Jan;94(1):38-42.Full text  Abstract

30. Mintzer DM, Billet SN, Chmielewski L. Drug-induced hematologic syndromes. Adv Hematol. 2009;2009:495863.Full text  Abstract

31. Jang HN, Bae EJ, Hwang K, et al. Hemolytic uremic syndrome associated with paraquat intoxication. J Clin Apher. 2014 Jun;29(3):183-6. Abstract

32. White NJ. Anaemia and malaria. Malar J. 2018 Oct 19;17(1):371.Full text  Abstract

33. Rajapakse P, Bakirhan K. Autoimmune hemolytic anemia associated with human babesiosis. J Hematol. 2021 Apr;10(2):41-5.Full text  Abstract

34. Hubl W, Mostbeck B, Hartleb H, et al. Investigation of the pathogenesis of massive hemolysis in a case of Clostridium perfringens septicemia. Ann Hematol. 1993 Sep;67(3):145-7. Abstract

35. Hashiba M, Tomino A, Takenaka N, et al. Clostridium perfringens infection in a febrile patient with severe hemolytic anemia. Am J Case Rep. 2016 Apr 6;17:219-23.Full text  Abstract

36. Shurin SB, Anderson P, Zollinger J, et al. Pathophysiology of hemolysis in infections with Haemophilus influenzae type b. J Clin Invest. 1986 Apr;77(4):1340-8.Full text  Abstract

37. Hill QA, Stamps R, Massey E, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017 Feb;176(3):395-411.Full text  Abstract

38. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020 May;41:100648. Abstract

39. Williams JD, Jayaprakash RK, Kithany H, et al. How to use Donath-Landsteiner test to diagnose paroxysmal cold haemoglobinuria (PCH). Arch Dis Child Educ Pract Ed. 2022 Jun;107(3):199-206.Full text  Abstract

40. American Society for Clinical Pathology. Thirty five things physicians and patients should question. Choosing Wisely, an initiative of the ABIM Foundation. 2021 [internet publication].Full text

41. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56(12):2015-38. Abstract

42. Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood. 1987 Mar;69(3):820-6.Full text  Abstract

43. Bain BJ. Diagnosis from the blood smear. N Engl J Med. 2005 Aug 4;353(5):498-507. Abstract

44. Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA. 1980 May 16;243(19):1909-11. Abstract

45. Galen RS. Application of the predictive value model in the analysis of test effectiveness. Clin Lab Med. 1982 Dec;2(4):685-99. Abstract

46. Oppenheim A, Jury CL, Rund D, et al. G6PD Mediterranean accounts for the high prevalence of G6PD deficiency in Kurdish Jews. Hum Genet. 1993 Apr;91(3):293-4. Abstract

47. Berentsen S. How I treat cold agglutinin disease. Blood. 2021 Mar 11;137(10):1295-303.Full text  Abstract

48. Reid M, Fedutes Henderson BA. Sutimlimab for cold agglutinin disease. J Adv Pract Oncol. 2024 Sep;15(6):389-95.Full text  Abstract

49. Röth A, Berentsen S, Barcellini W, et al. Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study part B. EClinicalMedicine. 2024 Aug;74:102733.Full text  Abstract

50. Röth A, Barcellini W, D'Sa S, et al. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease. Am J Hematol. 2023 Aug;98(8):1246-53.Full text  Abstract

51. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015 Apr;14(4):304-13. Abstract

52. Liu AP, Cheuk DK. Disease-modifying treatments for primary autoimmune haemolytic anaemia. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD012493.Full text  Abstract

53. Bussone G, Ribeiro E, Dechartres A, et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009 Mar;84(3):153-7.Full text  Abstract

54. Hill QA, Stamps R, Massey E, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017 Apr;177(2):208-20.Full text  Abstract

55. Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009 Jan;8(1):73-9. Abstract

56. Habermalz B, Sauerland S, Decker G, et al. Laparoscopic splenectomy: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc. 2008 Apr;22(4):821-48. Abstract

57. Cai Y, Liu Z, Liu X. Laparoscopic versus open splenectomy for portal hypertension: a systematic review of comparative studies. Surg Innov. 2014 Aug;21(4):442-7. Abstract

58. Zheng X, Dou C, Yao Y, et al. A meta-analysis study of laparoscopic versus open splenectomy with or without esophagogastric devascularization in the management of liver cirrhosis and portal hypertension. J Laparoendosc Adv Surg Tech A. 2015 Feb;25(2):103-11. Abstract

59. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 Feb;15(2):312-22.Full text  Abstract

60. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 Oct;18(10):2496-502.Full text  Abstract

61. Martí-Carvajal AJ, Anand V, Cardona AF, et al. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria. Cochrane Database Syst Rev. 2014 Oct 30;(10):CD010340.Full text  Abstract

62. Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133(6):530-9.Full text  Abstract

63. Iolascon A, Andolfo I, Barcellini W, et al. Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica. 2017 Aug;102(8):1304-13.Full text  Abstract

64. Recht J, Chansamouth V, White NJ, et al. Nitrofurantoin and glucose-6-phosphate dehydrogenase deficiency: a safety review. JAC Antimicrob Resist. 2022 Jun;4(3):dlac045.Full text  Abstract

65. Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am J Health Syst Pharm. 2018 Feb 1;75(3):97-104. Abstract

66. Grace RF, Barcellini W. Management of pyruvate kinase deficiency in children and adults. Blood. 2020 Sep 10;136(11):1241-9.Full text  Abstract

67. Al-Samkari H, Galactéros F, Glenthøj A, et al. Mitapivat versus placebo for pyruvate kinase deficiency. N Engl J Med. 2022 Apr 14;386(15):1432-42. Abstract

68. Glenthøj A, van Beers EJ, Al-Samkari H, et al. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial. Lancet Haematol. 2022 Oct;9(10):e724-32. Abstract

69. Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2019 Jan 23;(1):CD007798.Full text  Abstract

70. Meyer O, Stahl D, Beckhove P, et al. Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type. Br J Haematol. 1997 Sep;98(4):860-2. Abstract

71. Flores G, Cunningham-Rundles C, Newland AC, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993 Dec;44(4):237-42. Abstract

72. Shah FT, Porter JB, Sadasivam N, et al. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. Br J Haematol. 2022 Jan;196(2):336-50.Full text  Abstract

73. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014 Nov 6;124(19):2930-6.Full text  Abstract

74. Barcellini W, Zaninoni A, Fattizzo B, et al. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. Am J Hematol. 2018 Sep;93(9):E243-6.Full text  Abstract

75. Hoffman PC. Immune hemolytic anemia - selected topics. Hematology Am Soc Hematol Educ Program. 2009:80-6.Full text  Abstract

Use of this content is subject to our disclaimer